How many UTIs constitute a recurrent UTI?

A recurrent UTI is medically defined as two or more confirmed urinary tract infections within a 6-month period, or three or more infections within a 12-month period.

Why do I keep getting UTIs even after taking antibiotics?

Recurrent UTIs despite antibiotic treatment can occur due to antibiotic resistance, reinfection, incomplete eradication, or underlying anatomical or hormonal factors. A specialist evaluation with urine culture is essential.

Can recurrent UTIs be prevented?

Yes - recurrent UTIs can often be significantly reduced or eliminated with the right prevention strategy including low-dose antibiotic prophylaxis, vaginal estrogen therapy for postmenopausal women, behavioral modifications, and evidence-based supplements.

Do I need to see an infectious disease specialist or can my primary care doctor treat recurrent UTIs?

While primary care physicians can treat individual UTI episodes, recurrent UTIs benefit significantly from infectious disease specialist evaluation with specialized training in antibiotic resistance patterns and evidence-based prevention strategies.

Is long-term antibiotic use for UTI prevention safe?

Low-dose antibiotic prophylaxis for recurrent UTI prevention has a well-established safety record when properly managed. Specialists carefully select the safest antibiotic at the lowest effective dose and regularly reassess.

Does Atlas IDP accept insurance for recurrent UTI treatment?

Yes, Atlas Infectious Disease Practice accepts most major insurance plans. Call (561) 995-6971 to verify your specific insurance coverage before your appointment.

Investigational Oral Biologic Achieves 100% C difficile Clinical Cure in Preliminary Cohort

Impact on Patient Safety and Hospital Efficiency

Identifying Factors for Bloodstream Infections in Neonates in NICU

Nirmatrelvir/Ritonavir Reduces Post-Acute Mortality in Immunocompromised COVID-19 Patients

Measles Outbreak Grows to 5 States

Rising Mucormycosis Cases Drive Efforts for Spotlight on Treatment Research

Infectious Disease Treatments on FDA’s Watchlist for Q2 2025

WHO Issues First Reports on Diagnostics, Therapies For Fungal Infections

Humanizing Monoclonal Antibodies for Mucormycosis Treatment

VX-01 Monoclonal Antibody Targets Mucormycosis by Blocking Angioinvasion

Schedule an Appointment

Quick Links

Patient Forms

Contact Us